Central and peripheral nervous system toxicity of common chemotherapeutic agents

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 5, 2009, Pages 761-767

  Sioka, Chrissa ^a,b   Kyritsis, Athanassios P ^a,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Brain; Cancer; Central nervous system; Chemotherapy; Neurotoxicity

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DIHYDROFOLATE REDUCTASE; FLUDARABINE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; OXALIPLATIN; PACLITAXEL; SURAMIN; TACROLIMUS; TAXANE DERIVATIVE; THALIDOMIDE; VINCRISTINE;

ABDUCENS NERVE PARALYSIS; ACUTE DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; AKINETIC MUTISM; AMINO ACID METABOLISM; APHASIA; BIHEMISPHERIC LUCENCIES; BLINDNESS; BRADYCARDIA; BRAIN DISEASE; BRAIN DYSFUNCTION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INJURY; CATATONIA; CEREBELLUM DISEASE; CEREBRAL BLINDNESS; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; COMA; CONFUSION; CONSTIPATION; DEEP VEIN THROMBOSIS; DEMYELINATING DISEASE; DEPRESSION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG SAFETY; DYSESTHESIA; DYSTONIA; EDEMA; EPILEPTIC STATE; EYE DISEASE; FOLATE METABOLISM; FOLLICULAR LYMPHOMA; GERM CELL TUMOR; HUMAN; LEUKEMIA; LEUKOENCEPHALOPATHY; LEUKOPENIA; LYMPHOMA; METHIONINE METABOLISM; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PAIN; PARALYSIS; PARESIS; PARESTHESIA; PARKINSONISM; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REFLEX DISORDER; RISK FACTOR; SARCOMA; SEIZURE; SENSORY NEUROPATHY; SHORT SURVEY; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR; VITAMIN SUPPLEMENTATION; WEAKNESS;

ANTINEOPLASTIC AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; HUMANS; NEOPLASMS;

EID: 61449190676     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0876-6     Document Type: Short Survey

References (58)

1. S Quasthoff HP Hartung 2002 Chemotherapy-induced peripheral neuropathy J Neurol 249 9 17
2. TI Weng FF Shih WJ Chen 2004 Unusual causes of hyperammonemia in the ED Am J Emerg Med 22 105 107
3. J Dietrich J Marienhagen B Schalke U Bogdahn F Schlachetzki 2004 Vascular neurotoxicity following chemotherapy with cisplatin, ifosfamide, and etoposide Ann Pharmacother 38 242 246
4. SB Patten 2006 Psychiatric side effects of interferon treatment Curr Drug Saf 1 143 150
5. A Kovacs A Szomor I Abraham F Nagy H Losonczy 2002 Psychiatric sequelae of interferon-alpha therapy Orv Hetil 143 2183 2187
6. M Bannink WH Kruit AR Van Gool S Sleijfer B van der Holt AM Eggermont G Stoter MW Hengeveld 2008 Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated Psychosomatics 49 56 63
7. CA Meyers RS Scheibel AD Forman 1991 Persistent neurotoxicity of systemically administered interferon-alpha Neurology 41 672 676
8. W Jaksic D Veljkovic C Pozza I Lewis 2004 Methotrexate-induced leukoencephalopathy reversed by aminophylline and high-dose folinic acid Acta Haematol 111 230 232
9. M Linnebank S Malessa S Moskau A Semmler H Pels T Klockgether U Schlegel 2007 Acute methotrexate-induced encephalopathy-causal relation to homozygous allelic state for MTR c.2756A>G (D919G)? J Chemother 19 455 457
10. D Renard R Westhovens E Vandenbussche R Vandenberghe 2004 Reversible posterior leucoencephalopathy during oral treatment with methotrexate J Neurol 251 226 228
11. Y Terasawa S Nakane T Ohnishi M Harada K Furutani Y Izumi R Kaji 2007 Case of methotrexate encephalopathy: findings on diffusion tensor image and correlation with clinical outcome Rinsho Shinkeigaku 47 79 84
12. AF Eichler TT Batchelor JW Henson 2007 Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate Neuro Oncol 9 373 377
13. R Lai LE Abrey MK Rosenblum LM DeAngelis 2004 Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study Neurology 62 451 456
14. M Riga I Psarommatis S Korres M Varvutsi I Giotakis N Apostolopoulos E Ferekidis 2007 Neurotoxicity of vincristine on the medial olivocochlear bundle Int J Pediatr Otorhinolaryngol 71 63 69
15. RL Hurwitz DH Mahoney Jr DL Armstrong TM Browder 1988 Reversible encephalopathy and seizures as a result of conventional vincristine administration Med Pediatr Oncol 16 216 219
16. E Toker O Yenice MS Ogut 2004 Isolated abducens nerve palsy induced by vincristine therapy J AAPOS 8 69 71
17. RA Fleming 1997 An overview of cyclophosphamide and ifosfamide pharmacology Pharmacotherapy 17 146S 154S
18. KA David J Picus 2005 Evaluating risk factors for the development of ifosfamide encephalopathy Am J Clin Oncol 28 277 280
19. S Kilickap M Cakar IK Onal A Tufan H Akoglu S Aksoy M Erman G Tekuzman 2006 Nonconvulsive status epilepticus due to ifosfamide Ann Pharmacother 40 332 335
20. IS Park HJ Lee YS Lee JS Hwang MS Lee 2005 Ifosfamide-induced encephalopathy with or without using methylene blue Int J Gynecol Cancer 15 807 810
21. C Dufour J Grill P Sabouraud C Behar M Munzer J Motte O Oberlin A Paci O Hartmann 2006 Ifosfamide induced encephalopathy: 15 observations Arch Pediatr 13 140 145
22. WS Bartynski ZR Zeigler RK Shadduck J Lister 2004 Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation AJNR Am J Neuroradiol 25 261 269
23. AR Mueller KP Platz WO Bechstein N Schattenfroh G Stoltenburg-Didinger G Blumhardt W Christe P Neuhaus 1994 Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506 Transplantation 58 155 170
24. S Taque S Peudenier S Gie M Rambeau V Gandemer L Bridoux P Betremieux L De Parscau E Le Gall 2004 Central neurotoxicity of cyclosporine in two children with nephrotic syndrome Pediatr Nephrol 19 276 280
25. HA Teive IV Brandi CH Camargo MA Bittencourt CM Bonfim ML Friedrich CR de Medeiros LC Werneck R Pasquini 2001 Reversible posterior leucoencephalopathy syndrome associated with bone marrow transplantation Arq Neuropsiquiatr 59 784 789
26. J Cid M Revilla A Cervera F Cervantes E Munoz I Ferrer E Montserrat 2000 Progressive multifocal leukoencephalopathy following oral fludarabine treatment of chronic lymphocytic leukemia Ann Hematol 79 392 395
27. M Saumoy G Castells L Escoda R Mares C Richart A Ugarriza 2002 Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia after treatment with fludarabine Leuk Lymphoma 43 433 436
28. DR Spriggs E Stopa RJ Mayer W Schoene DW Kufe 1986 Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study Cancer Res 46 5953 5958
29. HG Chun BR Leyland-Jones SM Caryk DF Hoth 1986 Central nervous system toxicity of fludarabine phosphate Cancer Treat Rep 70 1225 1228
30. B Saito T Nakamaki H Nakashima T Usui N Hattori K Kawakami S Tomoyasu 2007 Reversible posterior leukoencephalopathy syndrome after repeat intermediate-dose cytarabine chemotherapy in a patient with acute myeloid leukemia Am J Hematol 82 304 306
31. DJ Vaughn JG Jarvik D Hackney S Peters EA Stadtmauer 1993 High-dose cytarabine neurotoxicity: MR findings during the acute phase Am J Neuroradiol 14 1014 1016
32. D Gottlieb K Bradstock J Koutts T Robertson C Lee P Castaldi 1987 The neurotoxicity of high-dose cytosine arabinoside is age-related Cancer 60 1439 1441
33. H Vogel DS Horoupian 1993 Filamentous degeneration of neurons. A possible feature of cytosine arabinoside neurotoxicity Cancer 71 1303 1308
34. LT Lucato AM McKinney J Short M Teksam CL Truwit 2006 Reversible findings of restricted diffusion in 5-fluorouracil neurotoxicity Australas Radiol 50 364 368
35. CH Takimoto ZH Lu R Zhang MD Liang LV Larson LR Cantilena Jr JL Grem CJ Allegra RB Diasio E Chu 1996 Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency Clin Cancer Res 2 477 481
36. C Barbieux B Patri I Cerf V de Parades 1996 Acute cerebellar syndrome after treatment with 5-fluorouracil Bull Cancer 83 77 80
37. MW Saif RH Wilson N Harold B Keith DS Dougherty JL Grem 2001 Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil Anticancer Drugs 12 525 531
38. AA Argyriou M Koltzenburg P Polychronopoulos S Papapetropoulos HP Kalofonos 2008 Peripheral nerve damage associated with administration of taxanes in patients with cancer Crit Rev Oncol Hematol 66 218 228
39. CC Verstappen TJ Postma AA Geldof JJ Heimans 2004 Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation Anticancer Res 24 2337 2341
40. H Openshaw K Beamon TW Synold J Longmate NE Slatkin JH Doroshow S Forman K Margolin R Morgan S Shibata G Somlo 2004 Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine Clin Cancer Res 10 461 467
41. AA Argyriou E Chroni A Koutras G Iconomou S Papapetropoulos P Polychronopoulos HP Kalofonos 2006 Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation J Pain Symptom Manage 32 237 244
42. JR Perry E Warner 1996 Transient encephalopathy after paclitaxel (Taxol) infusion Neurology 46 1596 1599
43. K Mayerhofer K Bodner B Saletu B Bodner-Adler P Anderer L Hefler A Kaider S Leodolter C Kainz 2000 Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients Wien Klein Wochenschr 112 1007 1013
44. CG Ziske B Schottker M Gorschluter U Mey R Kleinschmidt U Schlegel T Sauerbruch IG Schmidt-Wolf 2002 Acute transient encephalopathy after paclitaxel infusion: report of three cases Ann.Oncol 13 629 631
45. M von Schlippe CJ Fowler SJ Harland 2001 Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis Br J Cancer 85 823 826
46. A Pace A Savarese M Picardo V Maresca U Pacetti G Del Monte A Biroccio C Leonetti B Jandolo F Cognetti L Bove 2003 Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy J Clin Oncol 21 927 931
47. C Leonetti A Biroccio C Gabellini M Scarsella V Maresca E Flori L Bove A Pace A Stoppacciaro G Zupi F Cognetti M Picardo 2003 Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy Int J Cancer 104 243 250
48. L Bove M Picardo V Maresca B Jandolo A Pace 2001 A pilot study on the relation between cisplatin neuropathy and vitamin E J Exp Clin Cancer Res 20 277 280
49. Y Ito Y Arahata Y Goto M Hirayama M Nagamutsu T Yasuda T Yanagi G Sobue 1998 Cisplatin neurotoxicity presenting as reversible posterior leukoencephalopathy syndrome Am J Neuroradiol 19 415 417
50. C Verschraegen CA Conrad WK Hong 1995 Subacute encephalopathic toxicity of cisplatin Lung Cancer 13 305 309
51. EK Joseph X Chen O Bogen JD Levine 2008 Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy J Pain 9 463 472
52. HS Hochster A Grothey BH Childs 2007 Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity J Clin Oncol 25 4028 4029
53. L Gamelin M Boisdron-Celle A Morel AL Poirier V Berger E Gamelin C Tournigand A de Gramont 2008 Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy J Clin Oncol 26 1188 1189
54. S Wolf D Barton L Kottschade A Grothey C Loprinzi 2008 Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies Eur J Cancer 44 1507 1515
55. R Plasmati F Pastorelli M Cavo E Petracci E Zamagni P Tosi D Cangini P Tacchetti F Salvi I Bartolomei R Michelucci CA Tassinari 2007 Neuropathy in multiple myeloma treated with thalidomide: a prospective study Neurology 69 573 581
56. G Zara M Ermani R Rondinone S Arienti A Doria 2008 Thalidomide and sensory neurotoxicity: A neurophysiological study J.Neurol Neurosurg Psychiatry 79 1258 1261
57. L Mileshkin R Stark B Day JF Seymour JB Zeldis HM Prince 2006 Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring J Clin Oncol 24 4507 4514
58. P Tosi E Zamagni C Cellini R Plasmati D Cangini P Tacchetti G Perrone F Pastorelli S Tura M Baccarani M Cavo 2005 Neurological toxicity of long-term (> 1 year) thalidomide therapy in patients with multiple myeloma Eur J Haematol 74 212 216